The FDA has accepted Sanofi’s filing for approval of its Darzalex rival in relapsed/refractory multiple myeloma. Sanofi will learn whether the FDA will approve anti-CD38 antibody isatuximab by the end of April 2020.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,